December 20, 2019 8:50am

After an all-time high, is it time to continue to shrug-off or profit from anticipated declines?

Be careful what you wish for, sentiment is artificially propped-up by electronic trading

Pre-open indications: SELL – VSTM, SLDB, STML, AXGN, NTLA and ALNY; BUY – BLUE and CRSP

Welcome to my world of defining insight!


It’s an honor to be considered the “canary in the sector’s coal mine”!  I post about “indication intelligence” devoting my time to collection and analysis of information to assist investors in the perception of sector vulnerabilities and strengths – it’s more than opinion, the facts and truth need to be recognized!


Dow futures are UP +0.10% (+28 points), S&P futures are UP +0.07% (+2 points) and NASDAQ futures are UP +0.15% (+13 points)


U.S. stock index futures were slightly higher Friday morning;

European stocks were higher with the pan-European Stoxx 600 climbing +0.6% by mid-morning;

Asia Pacific stocks declined by the close, as U.S. markets broke a new record, with positive news on the trade front further boosting sentiment however, Japanese autos took a tumble in response to the new trade deal;


Data Docket: Q3 real GDP (gross domestic product) figures will be released at 8:30 a.m. ET. Personal income and consumer spending for November, core personal consumption expenditures (PCE) for November, and the latest Kansas City Federal Reserve survey will all be released.



Investors are listening, watching and sweeping aside news of U.S. President Trump’s impeachment – in disgust over the polarization and partisan attitudes however, the S&P 500 broke past 3,200 for the first time.


Is there a message …?

Where do these “numbers” leave the cell and gene therapy sector – in left field waiting for a fly ball while the infield waits for a bunt!


Thursday night’s post’s title:  “the sector jumped after two down sessions; the oversold were recognized while strength is still to be sold into.”

  • The NASDAQ closed UP +59.48 points (+0.67%);
  • The IBB closed up +0.59% and the XBI closed up +0.50%;
  • The range of the 13 upside was +0.09% (ADVM) to +8.33% (VSTM) while the 23 downside ranged from -0.06% (QURE) to -4.72% (RARE); 
  • 8 out of the 24 upside had higher than the 3 month average volume;
  • 5 out of the 12 downside had higher than the 3 month average volume;

Review the content of Q4’s market:

  • December registers 7  negative and 7 positive closes … so far
  • November registered 1 holiday, 12 positive and 8 negative close;
  • October registered 10 positive, 1 neutral and 14 negative closes;


Companies in my headlights – It’s your decision; I provide an idea and context:

Pre-open indications: SELL – VSTM, SLDB, STML, AXGN, NTLA and ALNY; BUY – BLUE and CRSP



Opinions expressed are those of the author and are subject to change, and not intended to be a forecast of future events, a guarantee of future results, nor investment advice.

Whether information or intelligence is good, bad or somewhere in between; I put into context what is relevant and useful for investors.  All investments are subject to risks. Investors should consider investment objectives.

Henry McCusker, the editor and publisher of RegMed Investors does not hold or have positions in securities referred to in this publication.